## Marie-Luise Berres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6228513/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Crosstalk between Muscularis Macrophages and Enteric Neurons Regulates Gastrointestinal Motility. Cell, 2014, 158, 300-313.	28.9	498
2	<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	8.5	346
3	Dietary Intake Regulates the Circulating Inflammatory Monocyte Pool. Cell, 2019, 178, 1102-1114.e17.	28.9	254
4	Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. Journal of Clinical Investigation, 2010, 120, 4129-4140.	8.2	227
5	CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology, 2010, 51, 1345-1353.	7.3	144
6	Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?. British Journal of Haematology, 2015, 169, 3-13.	2.5	141
7	Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17444-17449.	7.1	133
8	Inhibition of hepatic fibrogenesis by matrix metalloproteinaseâ€9 mutants in mice. FASEB Journal, 2006, 20, 444-454.	0.5	128
9	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962.	12.8	111
10	Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology, 2012, 55, 1610-1619.	7.3	110
11	A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. Journal of Hepatology, 2009, 50, 370-376.	3.7	75
12	Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology, 2011, 53, 596-603.	7.3	70
13	The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. Journal of Hepatology, 2008, 48, 208-215.	3.7	66
14	Longitudinal monocyte Human leukocyte antigenâ€DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver International, 2009, 29, 536-543.	3.9	63
15	Pathological Consequence of Misguided Dendritic Cell Differentiation in Histiocytic Diseases. Advances in Immunology, 2013, 120, 127-161.	2.2	61
16	CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Journal of Hepatology, 2015, 62, 332-339.	3.7	58
17	RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	8.5	58
18	The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice. PLoS ONE, 2013, 8, e66106.	2.5	58

MARIE-LUISE BERRES

#	Article	IF	CITATIONS
19	Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver International, 2011, 31, 840-849.	3.9	54
20	Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology, 2013, 57, 797-805.	7.3	51
21	Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB Journal, 2014, 28, 5136-5147.	0.5	51
22	Influence of Liver Fibrosis on Lobular Zonation. Cells, 2019, 8, 1556.	4.1	51
23	Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics, 2006, 6, 6538-6548.	2.2	42
24	Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. Journal of Clinical Gastroenterology, 2012, 46, 334-338.	2.2	37
25	Chemokine (Câ€X  motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver International, 2016, 36, 386-394.	3.9	36
26	Circulating <scp>CXCL</scp> 10 in cirrhotic portal hypertension might reflect systemic inflammation and predict <scp>ACLF</scp> and mortality. Liver International, 2018, 38, 875-884.	3.9	35
27	The chemokine scavenging receptor D6 limits acute toxic liver injury <i>in vivo</i> . Biological Chemistry, 2009, 390, 1039-1045.	2.5	28
28	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. Frontiers in Immunology, 2020, 11, 354.	4.8	27
29	Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Human Immunology, 2008, 69, 861-866.	2.4	25
30	Chemokines as Immune Mediators of Liver Diseases Related to the Metabolic Syndrome. Digestive Diseases, 2010, 28, 192-196.	1.9	22
31	Macrophage migration inhibitory factor exerts proâ€proliferative and antiâ€apoptotic effects via CD74 in murine hepatocellular carcinoma. British Journal of Pharmacology, 2021, 178, 4452-4467.	5.4	20
32	The chemokine receptor CXCR3 limits injury after acute toxic liver damage. Laboratory Investigation, 2012, 92, 724-734.	3.7	18
33	Interference with Oligomerization and Glycosaminoglycan Binding of the Chemokine CCL5 Improves Experimental Liver Injury. PLoS ONE, 2012, 7, e36614.	2.5	15
34	Met-CCL5 modifies monocyte subpopulations during liver fibrosis regression. International Journal of Clinical and Experimental Pathology, 2013, 6, 678-85.	0.5	14
35	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. JHEP Reports, 2021, 3, 100221.	4.9	12
36	Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. Cells, 2021, 10, 252.	4.1	11

MARIE-LUISE BERRES

#	Article	IF	CITATIONS
37	Platelet Factor 4 Attenuates Experimental Acute Liver Injury in Mice. Frontiers in Physiology, 2019, 10, 326.	2.8	10
38	Liver DCs in health and disease. International Review of Cell and Molecular Biology, 2019, 348, 263-299.	3.2	9
39	Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine, 2021, 8, 814496.	2.6	9
40	Therapeutic potential of chemokine receptor antagonists for liver disease. Expert Review of Clinical Pharmacology, 2011, 4, 503-513.	3.1	8
41	A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. Human Immunology, 2011, 72, 273-277.	2.4	8
42	Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib. Visceral Medicine, 2019, 35, 43-46.	1.3	6
43	Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies. Clinical and Translational Science, 2021, 14, 1853-1863.	3.1	6
44	Genetic Variants in the Promoter Region of the Macrophage Migration Inhibitory Factor are Associated with the Severity of Hepatitis C Virus-Induced Liver Fibrosis. International Journal of Molecular Sciences, 2019, 20, 3753.	4.1	5
45	<scp>JAMâ€A</scp> is a multifaceted regulator in hepatic fibrogenesis, supporting <scp>LSEC</scp> integrity and stellate cell quiescence. Liver International, 2022, 42, 1185-1203.	3.9	5
46	Extracellular Vesicles from Steatotic Hepatocytes Provoke Pro-Fibrotic Responses in Cultured Stellate Cells. Biomolecules, 2022, 12, 698.	4.0	3
47	Role of circulating angiogenin levels in portal hypertension and TIPS. PLoS ONE, 2021, 16, e0256473.	2.5	2
48	A Radiomics Approach to Predict the Emergence of New Hepatocellular Carcinoma in Computed Tomography for High-Risk Patients with Liver Cirrhosis. Diagnostics, 2021, 11, 1650.	2.6	1
49	THU-471-Establishment of a short-termed orthotopic transplantation model in C57/B6 mice that recapitulates characteristic features of human intrahepatic cholangiocarcinoma. Journal of Hepatology, 2019, 70, e367-e368.	3.7	0
50	Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia. Blood, 2013, 122, 103-103.	1.4	0
51	Novel short-termed mouse model of intrahepatic cholangiocarcinoma by orthotopic transplantation of Hep-55.1C in mice with human homology. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
52	CXCR3 is a key regulator during macrophage differentiation and has a significant impact on tumor-associated macrophages. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0